ZVRA at a glance
ZEVRA THERAPEUTICS, INC. (ZVRA, SEC CIK 1434647) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as August 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ZEVRA THERAPEUTICS, INC. (ZVRA) reported revenue of $106.5 million (up 350.9% from FY2024) and net income of $83.2 million. Diluted EPS was $1.35.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding ZEVRA THERAPEUTICS, INC. (ZVRA) shares worth $299.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Thompson Rahsaan on August 14, 2026 of 42,666 shares at $11.13 per share.
- In the last 90 days, ZVRA insiders reported 0 open-market purchases ($0) and 2 open-market sales ($613K) on Form 4, a net sale of $613K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $106.5M
- +350.9% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$613K
- 13F holders
- 26 funds
- $299.3M · +1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $39.7M, up $13.8M YoY from $25.9M, driven by MIPLYFFA sales up $8.7M
- Operating income $16.8M vs $71.0M operating loss YoY
- MIPLYFFA best-performing product, with product sales up $8.7M; OLPRUVA revenue $0.2M
- Operating cash flow $23.2M vs $(11.8)M YoY for six months ended June 30
- EMA CHMP negative opinion on arimoclomol; re-examination requested, while OLPRUVA sales and marketing scaled back
Risk Factors
- No material changes to risk factors from the most recent 10-K
- Carried-forward risks remain applicable without quarterly updates
- Rule 10b5-1 plan for up to 42,666 shares adopted by Chief Legal Officer
- Plan termination scheduled for December 31, 2026
AI summary of the ZVRA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results and corporate updates announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operating details
Item EX-99.1: Item EX-99.1
- Q2 net revenue $39.7M, up 53% YoY, with MIPLYFFA contributing $30.2M and global EAP reimbursements $9.0M
- Net income $8.8M, or $0.14 diluted EPS, versus $74.7M in Q2 2025 distorted by a $148.3M priority-review-voucher gain
Item 5.07: Submission of Matters to a Vote of Security Holders
- 78.37% of outstanding shares voted at the June 4, 2026 annual meeting
- Douglas W. Calder and Corey Watton elected as Class II directors through 2029
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 financial results and corporate updates announced for quarter ended March 31, 2026
- Conference call and webcast scheduled May 6, 2026, at 4:30 p.m. ET
AI summaries of ZVRA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ZVRA
Don't miss the next ZVRA filing
- Alerts as it files. A push when ZVRA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ZVRA, by share count.
- Ask anything. An AI agent that reads every ZVRA filing and answers with sources.
ZVRA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Thompson Rahsaan | Sell | Aug 14, 2026 | 42,666 | $11.13 |
| Watton Corey Michael | Sell | Aug 10, 2026 | 12,300 | $11.25 |
| Watton Corey Michael | M | Aug 10, 2026 | 12,300 | - |
| Watton Corey Michael | M | Aug 10, 2026 | 12,300 | $4.97 |
| Thompson Rahsaan | Sell | Jun 22, 2026 | 34,557 | $12.68 |
| Thompson Rahsaan | M | Jun 21, 2026 | 66,667 | - |
| Thompson Rahsaan | M | Jun 21, 2026 | 66,667 | - |
| Watton Corey Michael | A | Jun 4, 2026 | 30,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $23.6M | $106.5M |
| Operating Income | - | -$87.0M | -$62.9M |
| Net Income | -$46.0M | -$105.5M | $83.2M |
| Op. Margin | - | -368.5% | -59.1% |
| Net Margin | - | -446.9% | 78.2% |
| Balance Sheet | |||
| Total Assets | $172.3M | $178.1M | $284.7M |
| Equity | - | $39.7M | $154.7M |
| ROE | - | -266.0% | 53.8% |
| Per Share | |||
| EPS | $-1.30 | $-2.28 | $1.35 |
| Cash Flow | |||
| Operating CF | - | -$69.7M | -$1.6M |
| CapEx | $296K | $0 | $835K |
Source: XBRL data in ZEVRA THERAPEUTICS, INC. (ZVRA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ZVRA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $299.3M |
| Q1 2026 | 25 | $168.4M |
| Q4 2025 | 23 | $164.3M |
| Q3 2025 | 22 | $149.6M |
| Q2 2025 | 20 | $115.6M |
| Q1 2025 | 17 | $59.5M |
| Q4 2024 | 13 | $61.1M |
| Q3 2024 | 10 | $11.6M |
- FMR LLC (Fidelity)+1.70M (+53%)
- BlackRock+652.4K (+15%)
- D.E. Shaw & Co+460.5K (+54%)
- Dimensional Fund Advisors+404.0K (+73%)
- Invesco Ltd+231.5K (+704%)
- Citadel Advisors LLC−614.5K (-98%)
- Millennium Management−499.8K (-85%)
- Goldman Sachs Group−197.6K (-27%)
- JPMorgan Chase & Co−18.0K (-5%)
- Raymond James Financial−4.2K (-18%)
- Prudential Financial+35.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 156 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ZVRA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| SC 13G | May 6, 2026 | - | - | |
| 4 | Mar 26, 2026 | - | - | - |
| 4 | Mar 19, 2026 | - | - | - |
| 8-K | Mar 16, 2026 | - | Analysis | - |
| 10-K | Mar 9, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 4 | Feb 10, 2026 | - | - | |
| 4 | Feb 4, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ZVRA SEC filings: frequently asked questions
Are ZVRA insiders buying or selling?
In the last 90 days, ZEVRA THERAPEUTICS, INC. (ZVRA) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $613,152 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ZVRA stock?
As of June 30, 2026, the largest ZEVRA THERAPEUTICS, INC. (ZVRA) holders among the 13F filers tracked by SignalX were BlackRock ($73.3 million), FMR LLC (Fidelity) ($70.5 million), Vanguard Capital Management LLC ($37.8 million), State Street Corp ($24.1 million), D.E. Shaw & Co ($18.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ZVRA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ZEVRA THERAPEUTICS, INC. (ZVRA) reported revenue of $106.5 million (up 350.9% from FY2024) and net income of $83.2 million. Diluted EPS was $1.35. The figures come from the XBRL data in the 10-K.
What did ZVRA report in its latest 8-K?
ZEVRA THERAPEUTICS, INC. (ZVRA) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results and corporate updates announced for quarter ended June 30, 2026.
What are the latest ZVRA SEC filings?
ZEVRA THERAPEUTICS, INC. (ZVRA) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on August 17, 2026.
What is ZVRA's SEC CIK number?
ZEVRA THERAPEUTICS, INC. (ZVRA)'s SEC Central Index Key (CIK) is 1434647. EDGAR lists every ZVRA filing under that number.
Ask anything about ZVRA
The research agent reads ZVRA's filings, financials, insider trades and 13F holders, then answers with sources.